LeadIQ logo
Learn more at LeadIQ.com

Insights

Strategic merger Ikena Oncology merged with ImageneBio in 2025 and operates as ImageneBio, expanding its platform and potential collaboration opportunities in oncology drug development across solid tumors.

Financing momentum Recent private placement of $75M alongside ongoing funding activity indicates strong investor interest and capital runway to advance pipeline programs and potential partnerships.

Productive partnerships Past partnerships include AstraZeneca collaboration on IKNA programs and the ImageneBio merger, signaling openness to co-development, licensing, and strategic alliances with big pharma.

Leadership leverage Key executives with capital allocation and corporate development experience, including CFO/COO leadership, suggest readiness for scalable business development, licensing deals, and structured financing conversations.

Market positioning Focus on small molecule design for solid tumors positions the company in a competitive niche with potential synergy for co-development deals with oncology players seeking novel candidates and combination therapy opportunities.

Similar companies to Ikena Oncology (Merged with ImageneBio)

Ikena Oncology (Merged with ImageneBio) Tech Stack

Ikena Oncology (Merged with ImageneBio) uses 8 technology products and services including Amazon Web Services, Drupal, WordPress, and more. Explore Ikena Oncology (Merged with ImageneBio)'s tech stack below.

Media & News

Ikena Oncology (Merged with ImageneBio)'s Email Address Formats

Ikena Oncology (Merged with ImageneBio) uses at least 3 email formats:
Ikena Oncology (Merged with ImageneBio) Email FormatsExamplePercentage
FLast@ikenaoncology.comJDoe@ikenaoncology.com
89%
LFirst@ikenaoncology.comDJohn@ikenaoncology.com
8%
Last@ikenaoncology.comDoe@ikenaoncology.com
3%

Frequently Asked Questions

What is Ikena Oncology (Merged with ImageneBio)'s phone number?

Minus sign iconPlus sign icon You can contact Ikena Oncology (Merged with ImageneBio)'s main corporate office by phone at
+1-857-273-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Ikena Oncology (Merged with ImageneBio)'s stock symbol?

Minus sign iconPlus sign iconIkena Oncology (Merged with ImageneBio) is a publicly traded company; the company's stock symbol is IKNA.

What is Ikena Oncology (Merged with ImageneBio)'s official website and social media links?

Minus sign iconPlus sign iconIkena Oncology (Merged with ImageneBio)'s official website is ikenaoncology.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Ikena Oncology (Merged with ImageneBio) generate?

Minus sign iconPlus sign icon As of August 2026, Ikena Oncology (Merged with ImageneBio)'s annual revenue is estimated to be $1M - $10M.

What is Ikena Oncology (Merged with ImageneBio)'s SIC code and NAICS code?

Minus sign iconPlus sign iconIkena Oncology (Merged with ImageneBio)'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ikena Oncology (Merged with ImageneBio) have currently?

Minus sign iconPlus sign iconAs of August 2026, Ikena Oncology (Merged with ImageneBio) has approximately 12 employees across 3 continents, including North America, Europe and Africa. Key team members include Senior Director, Head Of Human Resources: S. D., Information Technology Manager: R. W. and Manager, Human Resources Operations: V. T. Explore Ikena Oncology (Merged with ImageneBio)'s employee directory with LeadIQ.

What industry does Ikena Oncology (Merged with ImageneBio) belong to?

Minus sign iconPlus sign iconIkena Oncology (Merged with ImageneBio) operates in the Biotechnology Research industry.

What technology does Ikena Oncology (Merged with ImageneBio) use?

Minus sign iconPlus sign iconIkena Oncology (Merged with ImageneBio)'s tech stack includes Amazon Web Services, Drupal, WordPress, CookieYes, NetSuite, Mailchimp, Microsoft 365 and Google Cloud.

What is Ikena Oncology (Merged with ImageneBio)'s email format?

Minus sign iconPlus sign iconIkena Oncology (Merged with ImageneBio)'s email format typically follows the pattern of FLast@ikenaoncology.com. Find more Ikena Oncology (Merged with ImageneBio) email formats with LeadIQ.

How much funding has Ikena Oncology (Merged with ImageneBio) raised to date?

Minus sign iconPlus sign icon As of August 2026, Ikena Oncology (Merged with ImageneBio) has raised $284M in funding. The last funding round occurred on Dec 23, 2024 for $40M.

When was Ikena Oncology (Merged with ImageneBio) founded?

Minus sign iconPlus sign iconIkena Oncology (Merged with ImageneBio) was founded in 2016.
Ikena Oncology (Merged with ImageneBio) logo

Ikena Oncology (Merged with ImageneBio)

Biotechnology ResearchMassachusetts, United States11-50 Employees

Based in Boston, Massachusetts, Ikena Oncology is a biotechnology research company focused on designing and developing small-molecule therapies for solid tumors. The organization collaborates with partners to advance oncology programs and has expanded its capabilities through strategic corporate moves, including the 2023 acquisition of Pionyr Immunotherapeutics. In 2025, the company merged with ImageneBio, forming a combined entity that operates under the ImageneBio name. Its customers are typically other biopharmaceutical and biotechnology groups seeking collaboration in cancer drug development. Positioned in the biotechnology research sector, the firm concentrates on targeted approaches to oncology. The business operates with a relatively small team based in Boston, reflecting a focused research footprint.

Section iconCompany Overview

Phone number
+1-857-273-****
Website
ikenaoncology.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
IKNA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $284M

    Ikena Oncology (Merged with ImageneBio) has raised a total of $284M of funding over 4 rounds. Their latest funding round was raised on Dec 23, 2024 in the amount of $40M as a Post IPO Equity.

  • $1M - $10M

    Ikena Oncology (Merged with ImageneBio)'s revenue is estimated to be in the range of $1M - $10M

Company Leadership

  • Senior Director, Head Of Human Resources at Ikena Oncology (Merged with ImageneBio)
    S. D.
    Senior Director, Head Of Human Resources
    Mobile Phone
  • Information Technology Manager at Ikena Oncology (Merged with ImageneBio)
    R. W.
    Information Technology Manager
    Mobile Phone
  • Manager, Human Resources Operations at Ikena Oncology (Merged with ImageneBio)
    V. T.
    Manager, Human Resources Operations
    Mobile Phone
  • Pharmaceutical Research And Development Leader at Ikena Oncology (Merged with ImageneBio)
    W. B.
    Pharmaceutical Research And Development Leader
    Mobile Phone
  • Senior Executive Assistant And Administrative Operations Partner at Ikena Oncology (Merged with ImageneBio)
    J. M.
    Senior Executive Assistant And Administrative Operations Partner
    Mobile Phone

Employee Directory

  • Senior Scientist at Ikena Oncology (Merged with ImageneBio)
    P. N.
    Senior Scientist
    Mobile Phone
  • Scientist at Ikena Oncology (Merged with ImageneBio)
    S. S.
    Scientist
    Mobile Phone
  • Employee at Ikena Oncology (Merged with ImageneBio)
    K. M.
    Mobile Phone
  • Employee at Ikena Oncology (Merged with ImageneBio)
    K. M.
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.